New drug shows promise for rare fat disorder
NCT ID NCT04159415
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested an experimental drug called REGN4461 in 16 people with generalized lipodystrophy, a rare condition where the body can't store fat properly, leading to severe metabolic problems. The drug aims to improve blood sugar and triglyceride levels. Participants received either the drug or a placebo for 8 weeks to see if it helps control these issues.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GENERALIZED LIPODYSTROPHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Regeneron Research Site
Bethesda, Maryland, 20892, United States
-
Regeneron Research Site
Ann Arbor, Michigan, 48105, United States
-
Regeneron Research Site
Dallas, Texas, 75390, United States
-
Regeneron Research Site
Piura, 2665, Peru
-
Regeneron Research Site
Moscow, 117036, Russia
-
Regeneron Research Site
Ankara, 06230, Turkey (Türkiye)
-
Regeneron Research Site
Diyarbakır, 21808, Turkey (Türkiye)
-
Regeneron Research Site
Izmir, 35100, Turkey (Türkiye)
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New hope for youngest kids with rare fat disorder
- Rare fat disorder drug under microscope: new safety data emerges
- Lifesaving drug made available for rare fat disorder patients
- New drug could help rare fat disorder patients
- New hope for rare fat disorder: experimental drug mibavademab under safety review